Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Rimegepant for Migraine Prevention in Japanese Subjects

NCT05399485 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT05399485
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05399485 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Rimegepant for Migraine Prevention in Japanese Subjects
Lead sponsor
Pfizer
Phase
Phase 3
Overall status
Completed
Start date
August 9, 2022
Completion date
November 7, 2024
Enrollment
496 (actual)
Sites
44

Conditions

As the registry lists them; a condition with its own page is linked.

migraine